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 Cone snails are predatory marine gastropods that use venom to capture 
prey. Components of the cone snail venom are small peptidic compounds called 
conotoxins which target ion channels, receptors, and transporters in the prey’s 
nervous system.  Conotoxins are highly potent and specific towards their 
molecular target, thus, they are used as tools for the understanding of how the 
nervous system works. Moreover, conotoxins are also powerful leads for 
developing new drugs. A conotoxin, -MVIIA is now sold as the drug Prialt for the 
treatment of pain. 
 Given the tremendous research and pharmacological applications of these 
compounds, it is thus important to pursue further research aimed at discovering 
novel conotoxins. For this research I aimed to discover novel conotoxins using 
two biological assays that were not previously used in conotoxin discovery. One 
assay measured the activity of the norepinephrine transporter (NET) expressed 
in human embryonic kidney (HEK) cells to reuptake radiolabeled norepinephrine 
and another assay used calcium imaging of dissociated mouse dorsal root 
ganglion (DRG) neurons. Further, I focused my research on cone snail clades 
with limited toxinological information. 
 Chapter 2 describes two conotoxins whose activities were identified using 
the NET assay. These conotoxins -AuID and -AoIC were isolated from the 
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venom of mollusk-hunters Conus aulicus and Conus araneosus, respectively. 
The conotoxin fv1a from Conus furvus another mollusk-hunting cone snail is also 
reported. The conotoxin fv1a does not inhibit NET, however, this conotoxin 
shows activity in vivo in mice and in calcium imaging of DRG neurons. The three 
conotoxins presented in Chapter 2 are homologous, however, they do not have 
the same pharmacological property. Thus, a comparison of the sequences of -
AuID, -AoIC, and fv1a allowed for the identification of amino acids important for 
NET inhibition. 
 Chapter 3 describes glycine-rich conotoxins identified from the venom of 
worm-hunting snails in the Virgiconus clade. vi6a, the first conotoxin identified in 
this group, was purified from the venom of Conus virgo using calcium imaging. 
This conotoxin elicited an excitatory behavior in mice when injected intracranially 
(IC) and intraperitoneally (IP). Conotoxins homologous to vi6a were further 
identified from Conus terebra and Conus kintoki using molecular biology 
techniques. Interestingly, C. virgo expresses two additional conotoxins 
homologous to vi6a.  
 Chapter 4 describes the characterization of pruriceptors in the mouse 
DRG that are responsive to histamine and chloroquine. Three major populations 
of neurons were identified and these populations were further characterized 
using various pharmacological agents to identify the constellation of ion channels 
and receptors expressed in the membrane of these neurons. Using the conotoxin 
-PIIIA, the expression of Nav1.7 and Nav1.8 in these pruriceptor populations 
were identified. 
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Cone snails (genus Conus) comprise a large group of predatory marine 
gastropods that inhabit the tropical waters around the world. This genus is 
species rich with ~850 known members and all of them use venom for various 
biotic interactions, including prey capture (Favreau and Stocklin 2009; Olivera 
2002; Röckel et al. 1995). There are three major groups of cone snails based on 
prey, these are fish-hunting (piscivores), mollusc-hunting (molluscivores) and the 
largest group, worm-hunting (vermivores) (Kohn 1959; McIntosh and Jones 
2001; Olivera 1997; Olivera et al. 1990). 
Humans have shown interest in cone snails since the dawn of civilization. 
An excavation form the ancient Mesopotamian city of Uruk discovered a 5000 
year old necklace made of cone snail shells (Terlau and Olivera 2004; Olivera et 
al. 2014). The keen interest of humans in cone snails is not surprising since cone 
snails possess arguably some of the most beautiful shells known to man. For 
example, a rare specimen of Conus cedonulli (the matchless cone) was priced 
higher than the painting “Woman in Blue Reading a Letter” by the Dutch master 
Johannes Vermeer at an auction in Europe in the late 18th century (Terlau and 
Olivera 2004; Olivera et al. 2014). 
 In some islands in the central Philippines, the cone snails, although not 
very abundant, are a food source for the local population. These snails can even 
be purchased in the local market. The snails are usually cooked with noodles or 
prepared as a broth flavored with local spices.  The locals report that the best 
tasting part of the snail is the foot whereas other parts of the cone snail have a 
gritty texture.  
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The scientific interest in cone snails stems from the fact that cone snail 
stings are extremely painful and some human stinging incidents proved fatal. 
One species for example, Conus geographus (the geography cone) has caused 
multiple human fatalities (Flecker 1936; Fegan and Andresen 1997). Other cone 
snail species are not as deadly as C. geographus, however, they can still deliver 
painful stings. People living in coastal areas in the Philippines know to be extra 
careful when handling all species of cone snails.  
Cone snails deliver lethal or painful stings because of the venom that the 
snail injects.  Venom is made in the snail’s venom gland. Attached to this gland is 
a muscular bulb that functions to push the venom out of the gland into the 
proboscis. At the tip of the proboscis is a radular tooth that pierces the prey and 
delivers venom (Olivera 2002). In some species, the tip of the radular tooth is 
barbed such that when the prey is stung it is effectively tethered to the snail 
(Kantor and Puillandre 2012; Olivera 1997). The components of the venom are 
called conotoxins/conopeptides which target ion channels, receptors, and 
transporters in the nervous system of the prey animals, predators, or competitors 
(Lebbe et al. 2014; Adams et al. 2012; Schroeder and Craik 2012). The 
conotoxins are small peptidic molecules generally 10 – 30 amino acids long 
(Olivera et al. 1985; Gray et al. 1988). The small size of these conotoxins is 
unique since peptidic venom components from other species are relatively large 
comprising of 40 – 80 amino acids (Olivera et al. 1990). Another striking feature 
of conotoxins is the abundance of posttranslationally modified amino acids. 
These modifications include the hydroxylation of proline (Cruz et al. 1985; Lopez-
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Vera et al. 2008), the glycosylation of threonine and serine (Craig et al. 1998; 
Craig et al. 1999), bromination of tryptophan (Rigby et al. 1999; Jimenez et al. 
2004), -carboxylation of glutamate (Bandyopadhyay et al. 1998; Rivier et al, 
1987), sulfation of tyrosine ( Wolfender et al. 1999), and conversion of L- to D-
amino acids (Buczek et al. 2005a; Buczek et al. 2008). Conotoxins are translated 
through conventional ribosomal pathways and the mRNA’s coding for each of 
these conotoxins can be isolated from the venom duct.  
Conotoxins are translated as a precursor with three distinct regions 
(Buczek et al. 2005b; Olivera 1997). The canonical conotoxin precursor consists 
of the signal sequence at the N-terminal, an intervening proregion, and the toxin 
coding region located at the C-terminal (Colledge et al. 1992; Robinson and 
Norton 2014). Analysis of the conotoxin precursor identified from different cone 
snail species revealed that conotoxins with conserved pattern of cysteine 
residues in the mature toxin have a correspondingly highly conserved sequence 
of amino acids in the signal sequence (Woodward et al. 1990; Santos et al. 2004; 
Corpuz et al. 2005; Walker et al. 1999). The conotoxins that display this pattern 
of conservation of amino acids in their precursor belong to the same gene 
superfamily (Terlau and Olivera 2004; Woodward et al. 1990). Moreover, 
conotoxins under a gene superfamily with the same pharmacological target fall 
under a conotoxin family (Terlau and Olivera 2004). For example, conotoxin 
family in the O1-superfamily include the -conotoxins, which target voltage-gated 
calcium channels (Hillyard et al. 1992; Olivera et al. 1985; Zhangsun et al. 2006), 
the -conotoxins, which target voltage-gated potassium channels (Shon et al. 
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1998; Terlau et al. 1996), and the - and the O-conotoxin families, which target 
different sites in voltage-gated sodium channels (Leipold et al. 2005; McIntosh et 
al. 1995; Shon et al. 1995; Terlau et al. 1996; Wilson et al. 2015). 
Conotoxins are evolved to be fast acting and extremely potent towards 
their ion channel and receptor target. This is expected since cone snails are slow 
moving animals that lack mechanical features that can be used to their 
advantage for predation, warding off competitors, or for defense. The molecular 
diversity of potential ion channel or receptor targets provides the evolutionary 
stimulus for the cone snails to develop a complex complement of fast acting 
peptides in their venom (Olivera and Teichert 2007).  
Homologues of ion channels and receptors in the snails prey, predator or 
competitor are also expressed by mammals. For example, injection of specific 
componen purified from the venom of the fish-hunting C. geographus into mice 
elicited aberrant behavior which include hyperactivity, shaking, scratching, 
excessive grooming, sleeping, sluggishness, seizures, barrel rolling, and, in 
some cases, death (Olivera et al. 1990). Research has shown that conotoxins 
has the ability to discriminate molecular isoforms of a particular ion channel 
family (Favreau et al. 1999; Olivera and Teichert 2007). Many of these ion 
channels exist in heteromeric combinations thus the number of possible isoforms 
of these ion channels is immensely large. For example, the voltage-gated 
potassium channel can be assembled from more than 80 gene products to create 
the functional tetrameric channel (Hille 2001; Jan and Jan 1997). The ability to 
discriminate related isoforms of a particular ion channel or receptor is especially 
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important for defining the physiological function of a specific ion channel isoform.  
An important implication that resulted from these studies is that conotoxins 
can be used to modulate the activity of their molecular targets. What this means 
is that conotoxins can be used as drugs for pathologies where their molecular 
target is involved. One conotoxin, -MVIIA, from Conus magus is in the market 
as Ziconotide (Prialt) used for the treatment of severe chronic pain (Klotz 2006; 
Sanford 2013; Williams et al. 2008). Several other conotoxins are undergoing 
different stages of clinical trials for the treatment of various diseases (Table 1.1). 
 Conotoxins are also used to probe the cell surface expression of their 
specific target. In a method called constellation pharmacology, conotoxins have 
proved useful in identifying cell surface expression of ion channels and receptors 
in populations of neurons and glia in the mouse nervous system. Constellation 
pharmacology uses calcium imaging to monitor cytosolic fluxes of calcium in a 
population of neuronal cells exposed to multiple compounds including conotoxins 
(Teichert et al. 2012; Smith et al. 2013).  A change in cytosolic calcium in 
response to any of these compounds indicates the cell surface expression of the 
receptor for that compound. For example, an increase in cytosolic calcium in 
response to the application of capsaicin indicates the presence of TrpV1 the 
capsaicin receptor. A series of application of these compounds identifies a group 
or a constellation of ion channels and receptor present in each of the cells in the 
experiment. Cells with the same profile of ion channels and receptor expression 
belong to a specific cell type. The identification of these cell types and the 
corresponding ion channels and receptors expressed by these cell types is an 
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important step in defining the physiological function mediated by these cells. 
Moreover, knowing the ion channels and receptors in these cell types also 
identifies potential pharmacological targets in conditions where a cell type is 
involved in particular disease. 
 Of the ~850 species of cone snail, only a small fraction of this number has 
been thoroughly probed for the conotoxins they express. Toxinological studies of 
cone snail involve testing the venom for activity against mice, a vertebrate 
animal. Thus, most of the cone snail species whose venom has been thoroughly 
researched belong to a group that hunts vertebrates: the fish-hunting cone snails. 
However, the mollusk- and the worm-hunting cone snails also express venom 
components that are active against ion channels or receptors expressed by 
vertebrates. The worm-hunting cone snails comprise the largest cone snail 
group, thus, there is still a huge number of cone snail species with very limited 
information about their venom. The characterization of conotoxins from these 
less studied cone snail species is important because these conotoxins have the 
potential to have unique biological and pharmacological activities and will prove 
extremely useful in research and drug development.  
 
Dissertation outline 
 For my dissertation, I made an attempt to purify and characterize 
conotoxins from mollusk- and worm-hunting snails. The cone snail species 
chosen for this work belong to clades where toxinological data are very limited. 
To achieve my goal, I will use bioactivity guided purification to purify the 
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conotoxins from venom and biochemically deduce the toxin sequence. Two kinds 
of assays were used in this research. One assay used calcium imaging to screen 
the venom for activity against a culture of mouse dorsal root ganglion (DRG) 
neurons, and another assay screened the venom for activity against a known 
molecular target, the norepinephrine transporter (NET). One of the major 
motivations in conducting this research is the fact the conotoxins are powerful 
tools in studying the nervous system. To illustrate, I used the conotoxin -PIIIA 
one of the pharmacological agents utilized to identify the expression of ion 
channels and receptors in a subset of DRG neurons that are sensitive to 
pruritogens. Chapter 2 of my dissertation describes a family of conotoxins 
identified from the Virgiconus clade. Members of this clade hunt worms. The first 
conotoxin in this family was purified from the venom of Conus virgo by following 
its ability in calcium imaging experiments to partially inhibit the increase in 
cytosolic calcium upon depolarization by external application of potassium 
chloride (KCl). These conotoxins are unusually glycine-rich and are expressed by 
members of the clade across a wide range of habitat. Chapter 3 talks about 
conotoxins from mollusk-hunting cone snails that belong to the T-superfamily. 
Three conotoxins are described in this chapter. Two conotoxins inhibit the 
reuptake of norepinephrine through the norepinephrine transporter (NET). 
Another conotoxin, although related to the NET-inhibiting conotoxins, does not 
inhibit NET at the concentrations used in the research. This conotoxin, however, 
is biologically active upon intra-cranial (IC) injection into young mice (17 – 21 
days old) and in the calcium imaging of dissociated mouse dorsal root ganglion 
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(DRG) neurons. In Chapter 4, I characterized populations of DRG neurons that 
respond to pruritogens. The characterization of these neurons involved using 
several pharmacological agents including conotoxins to probe for plasma 
membrane expression of ion channels and receptors in these populations of 
pruritogen-sensitive DRG neurons. In Chapter 5, I will summarize the results and 
look at the big-picture implications of my research. I will also discuss potential 
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T- SUPERFAMILY CONOTOXINS FROM MOLLUSK-HUNTING 
 CONE SNAILS: BIOLOGICAL ACTIVITY AND INHIBITION  






In this paper we report three vertebrate-active conotoxins purified from 
mollusk-hunting cone snails. These conotoxins belong to the T-superfamily and 
have the cysteine framework I (-CCXXXXCXOC-). Two conotoxins -AuId from 
Conus aulicus and -AoIc from Conus araneosus inhibit NET with IC50’s of 2.6 (± 
0.4) M and 0.7 (± 0.2) M, respectively.  The conotoxin fv1a from Conus furvus, 
although sharing 67% sequence identity with the NET-inhibiting conotoxins, did 
not inhibit NET, thus making it possible to identify residues that are functionally 
critical for NET inhibition. Interestingly, fv1a displayed activity in calcium imaging 
assays of dissociated dorsal root ganglion (DRG) neurons and upon intracranial 
(IC) injection into mice. We interpret these results to mean that a signaling 
molecule other than NET is an alternate target of conopeptides with a cysteine 
scaffold shared by -MrIa, -AuId, -AoIc, and fv1a. The discovery and 
characterization of these conotoxins suggest that: 1) the clade of mollusk-hunting 
cone snails contains a huge repository of compounds that inhibit NET, and 2) 
there is functional diversity within this group of homologous conotoxins 
expressed by the mollusk-hunters. 
 
Introduction 
The cone snails are venomous marine animals that inhabit tropical 
oceans. Based on predation behavior, the cone snails can be classified into three 
major groups: fish hunters (piscivores), mollusk hunters (molluscivores), and 
worm hunters (vermivores) (Kohn 1959; McIntosh and Jones 2001; Olivera et al. 
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1990; Olivera 1997). The vermivores are the largest group and probably retains 
the ancestral trait. There are ~850 species of cone snails and all of them use 
venom to capture their specific prey (Favreau and Stocklin 2009; Olivera 2002; 
Röckel et al. 1995). The cone snail venom primarily contains small peptidic 
molecules called conopeptides/conotoxins (Olivera et al. 1990; Olivera et al. 
1985; Teichert et al. 2015; Terlau and Olivera 2004).  
The conotoxins are gene products that are initially translated as a 
precursor (Buczek et al. 2005; Olivera 1997) with three regions: the signal 
sequence at the N-terminus, an intervening propeptide region, and the mature 
toxin region at the C-terminus (Colledge et al. 1992; Robinson and Norton 2014). 
Conotoxins that share a highly conserved signal sequence and a characteristic 
pattern of cysteine residues in the toxin region belong to a conotoxin superfamily 
(Terlau and Olivera 2004; Woodward et al. 1990). Members of a superfamily with 
the same biological target are further grouped into pharmacological families 
(Terlau and Olivera 2004).  
The T-superfamily is one of these conotoxin superfamilies and is widely 
expressed in cone snails across all feeding groups (Walker et al. 1999). The 
conotoxins in this superfamily are small (11 – 17 amino acids) and are 
structurally stabilized by two disulfide bonds (Walker et al. 1999). Members of the 
T-superfamily fall into two groups based on the framework of cysteine residues in 
the toxin region. One group has the cysteine framework V (CC-CC) (Terlau and 
Olivera 2004, Walker et al. 1999) while another group which includes the -
conotoxins has the cysteine framework I (CC-CXOC) (Terlau and Olivera 2004, 
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Walker et al. 1999). One member of the T-superfamily, the conotoxin -MrIA from 
Conus marmoreus was shown to inhibit the norepinephrine transporter (NET) 
(Sharpe et al. 2001). -MrIA has the cysteine framework I and is the founding 
member of the -conotoxin family in the T-superfamily. 
To our knowledge, -MrIA has been the only conotoxin reported to inhibit 
NET, and hence, the only known member of the -conotoxin family (Balaji et al. 
2000; McIntosh et al. 2000; Sharpe et al. 2001). -MrIA has been shown to be 
antinociceptive (McIntosh et al. 2000) and is currently undergoing clinical trials 
for the treatment of pain (Brust et al. 2009; Green et al. 2014). -MrIA was 
purified from the mollusk hunter C. marmoreus. We therefore reasoned that other 
mollusk-hunting cone snails potentially express conotoxins homologous to -
MrIa. The method of phylogeny-assisted conotoxin discovery has been 
successfully used in the search of novel conotoxins with specific activity (Azam 
and McIntosh 2009: Bulaj 2008; Espino et al. 2016; Olivera 2006; Olivera and 
Teichert 2007; Platt et al. 2014). 
In the search for novel conotoxins that inhibit NET, we focused on three 
species from the different clades of mollusk-hunting cone snails namely: Conus 
aulicus (Darioconus clade), Conus araneosus (Conus clade), and Conus furvus 
(Calibanus clade) (Figure 2.1) (Puillandre et al. 2014). In this paper, we identified 
and characterized the biological activities of three conotoxins belonging to the T-
superfamily. The pattern of cysteine residues indicates that these conotoxins 
belong to cysteine framework I. Bioactivity-guided purification identified the NET-
inhibiting conotoxin, -AuID, from the venom of Conus aulicus. A publication by 
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Gupta et al. (2010) identified the conotoxin Ar1311 from Conus araneosus which 
has the cysteine framework I. Our assay revealed that this conotoxin also inhibits 
the activity of NET. The third conotoxin, fv1a, a component of one of the major 
HPLC peaks in the C. furvus venom did not inhibit NET, but elicited cellular 
response monitored by calcium imaging of mouse dorsal root ganglion (DRG) 
neurons and induced aberrant behavior in mice upon intracranial (IC) injections. 
The conotoxins we report in this paper all have the cysteine framework I, 
however, the activities of these conotoxins are divergent indicating functional 
diversity of framework I conotoxins in the T-superfamily. 
 
Materials and methods 
Extraction and fractionation of crude venom.  Lyophilized venom (550 
mg) from Conus aulicus collected from the Philippines was extracted with 40 mL 
of a solution containing 40% acetonitrile (ACN) and 0.1% trifluoroacetic acid 
(TFA). The suspension was vortexed for 1 min and homogenized in a 50 mL 
glass-teflon homogenizer (5 cycles at 13,000 x g). The homogenate was 
vortexed for 10 s and centrifuged at 27,000 rpm for 10 min. The supernatant was 
diluted with a solution containing 0.1% TFA and applied on a preparative HPLC 
column. The components of the venom were eluted using a linear gradient of 
buffers consisting of 0.1% TFA (buffer A) and 90% ACN in 0.082% TFA (buffer 
B90). 
Conus furvus snails were purchased from a fish market in Guimaras 
Island, Philippines. The venom duct was dissected from 50 snails and the venom 
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was manually squeezed (in ice) out of the ducts and lyophilized. A 20-mg portion 
of the lyophilized venom was extracted with 1 mL solution containing 30% ACN 
and 0.1%TFA. The suspension was kept in ice and homogenized by vortexing 
every 10 min. After 30 min, the suspension was centrifuged at 13,000 x g for 15 
min and the supernatant was separated from the pellet. The extraction was 
repeated two more times and the supernatants from the three extractions were 
pooled and diluted to 3 times of the original volume with 0.1% TFA. This solution 
was then fractionated on Vydac C18 semipreparative column (5 m, 10mm x 250 
mm). The venom components were eluted using a linear gradient by mixing 0.1% 
TFA (Buffer A) and 90% ACN in 0.1% TFA (Buffer B90). The absorbance at 220 
nm was monitored and individual peaks corresponding to individual fractions 
were collected. 
Purification of conotoxins from C. aulicus and C. furvus.  The 
peptides from C. aulicus, and C. furvus were further purified by analytical reverse 
phase chromatography using a Vydac C18 monomeric column (5 m, 4.6 mm x 
250 mm). Separation of components contained in the norepinephrine-transporter-
inhibiting fraction obtained by preparative HPLC of C. aulicus venom was 
accomplished using a linear gradient constructed by mixing 30% - 50% Buffer 
B90 with Buffer A over the course of 20 min at a flow rate of 1 mL/min. Sample 
homogeneity was verified by secondary analytical HPLC applying the same 
gradient as the semipreparative HPLC. Major components in the C. furvus 
venom were purified by analytical HPLC. The conotoxin fv1a was one of the 
major component and was purified using a gradient of 10% - 30% B90 over 20 
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min at a flow rate of 1 mL/min. The purity of fv1a was verified by secondary 
analytical HPLC applying the same gradient. 
Reduction and alkylation of the purified peptides.  Purified peptides 
from C. aulicus, and C. furvus were reduced using dithiothreitol (DTT) and 
alkylated using 4-vinylpyridine (4-VP). In these reactions the pH was buffered to 
pH 8 using 0.5 M Tris base, reductant was added to a final concentration of 10 
mM DTT and the temperature was maintained a 65 ⁰C for 30 min. Subsequent 
alkylation was initiated by adding 0.8 L of 4-VP and proceeded in the dark, at 
room temperature, for 30 min. The reduced and alkylated peptide was purified 
from the reaction using an analytical reverse-phase HPLC column. 
Peptide sequencing.  Approximately 70 pmol of the alkylated peptide 
was sequenced by Edman degradation at the the DNA/peptide core facility, 
University of Utah. The 3-phenyl-2-thiohydantoin amino acid derivatives were 
identified by HPLC.  
Mass spectrometry.  MALDI mass analysis was performed using the 
Applied Biosystems Voyager System 4271 scanning over the m/z range between 
0.7 – 3 kDa in the reflector mode. 
Identification and sequencing of clones encoding Conus aulicus -
AuID.  cDNA from C. aulicus was used as a template for polymerase chain 
reaction (PCR) with oligonucleotides corresponding to conserved regions of the 
signal sequence and 3’ UTR sequences of Chi-prepropeptides. The resulting 
PCR products were purified using the High Pure PCR Product Purification Kit 
(Roche Diagnostics, Indianapolis, IN) following the manufacturer’s suggested 
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protocol. The eluted DNA fragments were annealed to pAMP vector using the 
CloneAmp pAMP System for Rapid Cloning of Amplification Products (Life 
Technologies/Gibco BRL, Grand Island, NY) following manufacturer’s suggested 
protocol and the resulting products transformed into DH5 competent cells. The 
nucleic acid sequences of these Chi-encoding clones were determined according 
to the standard protocol for automated sequencing. 
Identification and sequencing of clones encoding Conus furvus fv1a.  
cDNA from Conus furvus was used as a template for polymerase chain reaction 
(PCR) with oligonucleotides corresponding to conserved regions of the signal 
sequence and 3’ UTR sequences of Chi-prepropeptides. The resulting PCR 
products were purified using the High Pure PCR Product Purification Kit (Roche 
Diagnostics, Indianapolis, IN) following the manufacturer’s suggested protocol. 
The eluted DNA fragments were annealed to pNEB206A vector using the USER 
Friendly Cloning kit (NewEngland BioLabs, Inc., Beverly, MA) following 
manufacturer’s suggested protocol and the resulting products transformed into 
DH5 competent cells. The nucleic acid sequences of these Chi-encoding clones 
were determined according to the standard protocol for automated sequencing. 
Peptide synthesis.  The peptide -Au1D was synthesized at the 
DNA/Peptide Facility at the University of Utah. The peptides fv1a and Ar1311 
were synthesized with an Apex 396 automated peptide synthesizer (AAPPTec, 
Louisville, KY) using a standard solid-phase Fmoc (9-
fluorenylmethyloxycarbonyl) protocol. Ar1311 (-AoIC) was syntheseized on 
Fmoc-L-Cys(Acm)-Wang resin (substitution: 0.55 mmolg-1, Peptides 
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International Inc, Louisville, KY) and Fv1a on Fmoc-L-Pro-2-Cl-Trt 
resin(substitution: 0.9 mmolg-1, AAPPTec, Louisville,KY). All standard amino 
acids were purchased from AAPPTec and N-α-Fmoc-(O-tBu)-L-trans-4-
hydroxyproline form NovaBiochem (Merck KGaA, Darmstadt, Germany). Side-
chain protection for the following amino acids was: Asp and Hyp: O-tert-butyl 
(OtBu); Arg: 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf), Lys: tert-
butyloxycarbonyl (Boc); Tyr and Thr: tert-butyl (tBu); His: trityl (Trt). In order to 
control oxidative folding of the cysteines, orthogonal protection was used: one 
pair of Cys (Cys 1 and Cys 4) was Trt protected; the second pair (Cys 2 and Cys 
3) was protected with acetamidomethyl (Acm) group. Peptides were synthesized 
on 50 mol scale. Coupling activation was achieved with one equivalent of 0.4 M 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) 
and two equivalents of 2 M N,N-diisopropylethyl amine (DIPEA) in N-methyl-2-
pyrrolidone (NMP) and ten-fold excess of amino acid. Each coupling reaction 
was conducted for 60 min. Fmoc deprotection reaction was carried out for 20 min 
with 20% piperidine in DMF.  
Oxidative folding of the linear peptides.  The linear peptide was 
cleaved from 25 mg of resin using 1 mL reagent K (11.0 M TFA, 3.0 M 
ethanedithiol (EDT), 4.0 M thioanisole (TIS) and 0.5 M phenol), and precipitated 
in ice-cold methyl tert-butyl ether (MTBE). After the removal of MTBE, the 
precipitate was resuspended in buffer A (0.1% TFA) and purified using a Vydac 
C18 semipreparative reverse-phase column. Peptide folding was achieved in two 
steps. The first disulfide bridge was formed by incubating the linear peptide in a 
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solution containing 1.0  mM GSSG, 2.0 mM GSH, 100 mM Tris (pH = 7.5) and 
0.1 mM EDTA for 2 h. The folded peptide was separated from the solution by 
semipreparative HPLC. The formation of the second disulfide bridge was 
achieved by incubating the peptide for 20 min in a solution containing 24% ACN 
(v/v), 380.0 mM TFA and 5.0 mM I2. The folded peptide was purified by reverse 
phase analytical chromatography on a C18 HPLC column. The identity of the 
folded peptide was confirmed by mass spectrometry and co-elution with the 
native peptide isolated from venom. 
Cell culture.  Human embryonic kidney cells stably expressing the human 
norepinephrine transporter (HEK293-hNET) were grown in Dulbecco’s modified 
Eagle’s media  containing 10% (v/v) FBS, 100 units/mL penicillin, 100 g/mL 
streptomycin, 2 mM L-glutamine, and 250 g/mL G418 at 37 0C and 5% CO2 in a 
humidity controlled incubator.  
Norepinephrine uptake assay.  The norepinephrine uptake assay 
followed the protocol described in Galli et al. (1995). HEK293-hNET cells were 
plated at a density of approximately 50,000 cells/well on an amine coated 96-well 
tissue culture plates 1 day before the experiment. On the day of the experiment, 
the medium was aspirated and the cells washed once with Krebs-Ringer’s-
HEPES (KRH) buffer (130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM 
MgSO4, 1.2 mM KH2PO4, 10 mM HEPES, 1.8 g/L dextrose, pH 7.4). The cells 
were preincubated with the conotoxins for 10 min at 37 0C in KRH buffer 
supplemented with 100 mM L-ascorbate, 100 mM pargyline, and 10 mM U-
0521(catechol O-methyl transferase inhibitor). Uptake assay was initiated by the 
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addition of norepinephrine, Levo-[ring-2, 5, 6-3H] to a final concentration of 50 
nM. The uptake assay was performed at 37 0C for 15 min and terminated by 
rapid aspiration of the uptake buffer followed by 2 washes with 200 L ice-cold 
KRH buffer. The cells were then lysed with 100 L of a 10% SDS solution at 
room temperature with gentle shaking for 60 min. Accumulated radioactivity in 
the 50 L of the lysate was measured using liquid scintillation spectrometry. The 
remaining 50 L of the lysate was used to measure protein concentration using 
the DC protein assay kit (BioRad), following the manufacturer’s protocol. A 
parallel experiment was performed in the presence of 1.0 M desipramine to 
account for nonspecific uptake.  
Mouse bioassay.  Experimental protocols for experiments involving live 
animals were approved by the Institutional Animal Care and Use Committee 
(IACUC) of the University of Utah. Mice (17 – 21 days) were injected 
intracranially (IC) with peptide in 10 L saline solution. Mice were observed for 
aberrant behavior for 3 h. 
Calcium imaging assay.  Experimental protocols for experiments 
involving live animals were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of Utah. Dissection of the dorsal root 
ganglia (DRG) was done following previously described protocols (Teichert et al. 
2012; Smith et al. 2013). Lumbar DRG neurons from wild type C57/BL6 mouse 
were dissociated, pooled, and cultured overnight for calcium imaging 
experiments. Cells were loaded with Fura-2-AM dye one hour before the 
experiment. During the experiment, the dye inside the cells was excited 
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alternately with 340 nm and 380 nm light. The ratio of the emission 510 nm from 
both excitations was measured. The ratio of the fluorescence intensity is a 
measure of the increase in intracellular calcium resulting from the depolarization 
caused by the external application of 25 mM KCl. KCl was applied every 7 min. 
After the third KCl pulse, 1.5 M fv1a was applied and its effects on the levels of 
intracellular calcium were monitored. 
 
Results 
Purification, characterization and sequencing of a -conotoxins from 
C. aulicus.  High performance liquid chromatography (HPLC) purification of -
AuID was achieved by following its activity to inhibit the reuptake of 
norepinephrine (NE) via the human norepinephrine transporter (hNET) 
heterelogously expressed in human embryonic kidney (HEK) cells. Fractions 
from the semipreparative HPLC (Figure 2.2A) of the crude Conus aulicus venom 
were screened for activity against NET. The active fraction was further purified to 
homogeneity by analytical HPLC (Figure 2.2B-C). 
Matrix-assisted laser desorption ionization (MALDI) mass analysis of the 
active homogeneous sample revealed a single peptide with a mass of 1332.4 Da. 
The reduced and alkylated peptide has a mass of 1752.6 Da. The change in 
mass can be attributed to the alkylation of four cysteine residues by 4-
vinylpyridine (105 Da). Edman chemical analysis revealed a 12 amino acid 
peptide with the sequence SVCCGYKLCFOC where O indicates a proline post-
translationally modified to a hydroxyproline. The mass predicted from this 
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sequence is 1333.6 Da which differs by +1.2 Da from the mass of the native 
peptide obtained by MALDI mass analysis, suggesting the posttranslational 
modification of the peptide C-terminus into an amide. These results are 
consistent with the peptide sequence: SVCCGYKLCFOC-NH2 (Table 2.1). Since 
this peptide inhibits NET, we propose to call this peptide -AuId following the 
nomenclature for naming conotoxins (Olivera and Cruz 2001). 
Purification, characterization, and sequencing of fv1a.  Purification of 
the major HPLC fractions in the venom of Conus furvus led to the identification of 
the conotoxin fv1a (Figure 2.3A-C). MALDI mass analysis revealed the mass of 
the native peptide to be 1286.4 Da. Edman chemical analysis determined the 
sequence to be: GVCCAHTGCKOCP (Table 2.1) where O is a hydroxyproline 
residue. The predicted mass of this sequence is 1286.5 Da in agreement with the 
experimental mass of the native peptide measured by MALDI-MS and indicating 
the C-terminus is unmodified. A comparison of the fv1a sequence with those of 
the-conotoxins (Table 2.1) revealed a conserved pattern of cysteine residues 
and a conserved loop size between the cysteine residues.  
Peptide synthesis and folding.  The correctness of the sequence 
assignment of -AuID and fv1a was verified by HPLC co-elution experiments of 
the synthetic and venom-derived peptides. The linear peptides were oxidatively 
folded, and the major components from these folding reactions were purified to 
>99% homogeneity. MALDI mass analysis of the products of the folding reactions 
revealed a mass of 1322.5 Da for the synthetic -AuID and a mass of 1286.4 Da 
for the synthetic fv1a. The synthetic -AuID and fv1a each co-eluted with their 
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corresponding native peptides (Figure 2.4). These results verify the sequence 
assignments for -AuID and fv1a and demonstrate that each mature toxin is able 
to correctly fold without assistance if provided with an appropriate redox 
environment. Folding instructions are thus intrinsic to the mature toxin sequence 
and not inscribed in the propeptide. 
Ar1311 was synthesized following the sequence and disulfide connectivity 
determined by Gupta et al. (2010). In the paper the peptide was reported to have 
the sequence: RCCGYKMCHOC (Table 2.1) and stabilized by disulfide bonds 
between Cys1 and Cys4 and between Cys2 and Cys3. The linear Ar1311 was 
oxidatively folded and the major component was purified to >99% homogeneity. 
MALDI mass analysis of the folding reaction product yielded a mass of 1311.3 
Da which is consistent with the reported mass of the peptide. 
NET uptake assay.  Ar1311 was previously identified by Gupta et al. 
(2010) using mass spectrometric methods. The sequence of this peptide is 
shown in Table 2.1. The amino acid sequence of Ar1311 shows a high degree of 
similarity with the amino acid sequence of -conotoxins, thus Ar1311 is a 
potential NET antagonist.  Ar1311 was synthesized and tested for activity against 
NET. Results from the assay showed that Ar1311 inhibits the activity of the 
transporter (Figure 2.5). Since Ar1311 has the same pharmacological activity as 
the -conotoxins we propose to rename this peptide -AoIC following the rules 
for naming conotoxins (Olivera and Cruz 2001). The conotoxin fv1a failed to 
show any activity even at concentrations as high as 200 M (Figure 2.5). The 




Further characterization of the activity of both -AoIC and -AuID against 
NET showed that these peptides inhibit the transporter in a dose-dependent 
manner (Figure 2.5). Experiments using increasing concentrations of -AuID and 
-AoIC were performed to determine the concentration of conotoxin required to 
inhibit 50% of transporter activity (IC50). These experiments showed the IC50 of -
AoIC to be 0.7 ± 0.2 M and that of -AuID to be 2.6 ± 0.4 M. The alignment of 
the sequences of -AuID, -AoIC and the previously identified NET inhibitor -
MrIA, a conotoxin that belongs to the T-superfamily (McIntosh et al. 2000) 
revealed a striking conservation in the amino acid sequences of the conotoxins 
especially in the region between Cys2 and Cys3 (Table 2.1). These peptides 
share identical pharmacology hence fall under the -conotoxin family in the T-
superfamily. 
cDNA cloning and precursor sequence of fv1a and -AuID.  Conotoxin 
fv1a did not inhibit NET, and is thus pharmacologically different from the -
conotoxins, however, the conserved arrangement of cysteine residues in these 
peptides suggests that fv1a belongs to the same conotoxin superfamily as -
AuID and -AoIC. Conotoxins that belong to the same superfamily have a highly 
conserved signal sequence as well as conserved pattern of cysteine residues in 
the toxin region. Therefore, we determined the precursor sequences of fv1a and 
-AuId to rigorously test the hypothesis that fv1a belongs in the same 
superfamily as the -conotoxins.  
The cloned cDNA sequences encoding precursors of -AuID and fv1a 
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displayed the canonical organization typical for a conotoxin precursor (Figure 
2.6). As expected, the signal sequences found at the predicted N-terminus are 
composed primarily of hydrophobic amino acids. The signal sequence is followed 
by the pro-region and the toxin coding region is found at the C-terminal. The 
position corresponding to the hydroxyprolines in -AuID and fv1a is expectedly 
occupied by prolines in the clones.  Moreover the C-terminal of the -AuID 
precursor contains a glycine residue. The presence of C-terminal glycine is 
expected since it was shown that the native -AuId is amidated at the C-terminal. 
The C-terminal glycine in conotoxins is posttranslationally modified into an amide 
(Ul-Hasan et al. 2013).  
Sequence alignment of the precursors of fv1a, -AuID, and -MrIA (Figure 
2.6) revealed that that only 8 of the 24 amino acids in the signal sequence are 
not conserved. This high degree of conservation of amino acids in the signal 
sequence indicates that fv1a like the -conotoxins is a member of the T-
superfamily. The conclusion that fv1a belongs to the T-superfamily is further 
supported by the conserved pattern of cysteine residues between fv1a and -
conotoxins.  
 Biological activity of fv1a. Two assays tested whether fv1a exhibits 
biological activity in mice. One assay followed the behavior after intracranial (IC) 
injection. The other assay measured changes in intra-cellular calcium ion 
concentration of dissociated mouse dorsal root ganglion (DRG) neurons following 
membrane depolarization (Figure 2.7).  
IC injection of fv1a caused a hyperactive phenotype in young mice (17 – 
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21 day old). The hyperactive behavior was manifested by the animals running, 
climbing and jumping in cages. Interestingly, peptide doses as low as 0.1 nmol 
elicited this hyperactive behavior. Control subjects showed no difference in 
behavioral activity following IC injection of saline. In comparison, -MrIA causes 
a sluggish phenotype in mice (McIntosh et al. 2010) while  a related peptide, 
CTMrVIA that lacks the first two amino acids of -MrIA at the N-terminus, causes 
seizures and death in mice (Balaji et al. 2000). Calcium imaging of dissociated 
DRG neurons in the presence of 1.5 M fv1a resulted in partial inhibition of 
intracellular calcium increase upon depolarization using 25 mM KCl (Figure 2.7). 
A similar concentration of the -conotoxins potentiates the calcium response 
upon depolarization using 25 mM KCl (Figure 2.7). The behavioral and cellular 
responses resulting from the application of fv1a suggest that the peptide acts on 
a component of the mouse nervous system. Since fv1a does not inhibit NET in 
vitro and elicits behavioral and cellular responses that are different from the 
behavioral and cellular responses elicited by the -conotoxins, we conclude that 
the molecular target of fv1a is different from the target of -conotoxins. 
 
Discussion 
 Phylogeny-directed discovery has been successfully employed in the 
search of conotoxins with novel pharmacological properties (Azam and McIntosh 
2009; Bulaj 2008; Espino et al. 2016; Olivera 2006; Olivera and Teichert 2007; 
Platt et al. 2014). The information inferred from phylogenetic relationships among 
cone snails aided in the discovery of three conotoxins namely: -AuId, -AoIc, 
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and fv1a. These conotoxins were purified from the venom of mollusk-hunting 
cone snails C. aulicus (-AuID), C. araneosus (-AoIC), and C. furvus (fv1a). In 
this study, we investigated whether different groups of mollusk-hunting snails 
express conotoxins that inhibit the reuptake of norepinephrine (NE) through the 
norepinephrine transporter (NET). Previously it had been shown that a mollusk-
hunter (C. mamoreus) expresses the conotoxin -MrIa which inhibits the 
reuptake of NE via NET (Sharpe et al. 2001). We hypothesized that other 
mollusk-hunting snails also express conotoxins that inhibit NET. Our hypothesis 
was validated when the NET-inhibiting conotoxins -AuID and -AoIC were 
identified from the venom of C. aulicus and C. araneosus, respectively. 
Surprisingly, the conotoxin fv1a did not inhibit the activity of NET although it 
appears to be related to the -conotoxins. The conotoxin fv1a is biologically 
active when injected intracranially (IC) into mice and in the calcium imaging of 
dissociated mouse dorsal root ganglion (DRG) neuron.  
The conotoxins -AuID and -AoIC share the same pharmacological 
activity and are members of the -conotoxin family. The -conotoxins belong to 
the larger T-superfamily. The conotoxin fv1a shares the same cysteine 
framework as the -conotoxins. Moreover, analysis of the precursor sequence of 
fv1a and -AuID revealed a very high degree of similarity of the amino acids in 
the signal sequence. These results indicate that fv1a is also a member of the T-
superfamily. fv1a does not inhibit NET however the in vivo activity of this 
conotoxin in mice and its inhibition of the cytosolic influx of calcium in response 
to the application of high external [K+]o indicate that the target of this peptide is 
35 
 
biologically relevant in mammals. The characterization of the conotoxins reported 
in this paper indicates the diversity in the biological activity of framework I 
conotoxins in the T-superfamily. The conotoxin fv1a could potentially define a 
new family in the T-superfamily with a unique biological and pharmacological 
activity. 
The inability of fv1a to inhibit NET allowed the opportunity to perform a 
nature-designed structure activity relationship (SAR) studies to identify amino 
acids critical for the inhibition of NET. A comparison of fv1a, -AuIdD, -AoIC, 
and -MrIA sequences (Table 2.1) revealed that the amino acids in the first loop 
between the second cysteine (Cys2) and the third cysteine (Cys3) are highly 
divergent between NET inhibitors and non-NET inhibitors (e.g.,between-AuID 
and fv1a) whereas the same region is conserved between conotoxins that inhibit 
NET (e.g., -AuID and -AoIC). Conservative amino acid substitution in the 
region between Cys2 and Cys3 is tolerated. For example, a substitution of the 
leucine residue in -AuID with a methionine in -AoIC did not affect the ability of 
these peptides to inhibit NET. These observations suggest that the amino acids 
between Cys 2 and Cys 3 are important determinants for activity against NET.  
Changes in the second loop between Cys3 and Cys4 do not appear to affect 
NET activity as demonstrated by -AuID and -AoIC. The results of the natural -
conotoxin SAR are similar to those obtained from the SAR studies of - MrIA 
(Brust et al. 2009). 
The framework I conotoxins in the T-superfamily appear to be restricted to 
mollusk-hunting cone snails. A systematic screen (unpublished data) of cone 
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snails across different clades identified these conotoxins only in mollusk-hunters. 
It is highly probable that these conotoxins are important for prey capture. The -
conotoxins, for example, are possibly used in predation through the perturbation 
of noradrenergic signaling in their molluskan prey since norepinephrine acts as a 
neurotransmitter in mollusks (Adamo 2008; Lacoste et al. 2001; Sloley et al. 
1990). The conotoxins reported in this paper suggest that the clade of mollusk-
hunting cone snails contains a huge repository of compounds that inhibit NET. 
Thus, it is important for continued research on this group of cone snails to 
discover more NET-inhibiting conotoxins. These conotoxins would prove useful in 
research and medicine. 
The reuptake of norepinephrine through NET is the mechanism which 
terminates noradrenergic signaling.  NET has been implicated in various 
neuorological conditions and compounds that target NET have been developed 
as drugs for the treatment of diseases such depression, attention-deficit 
hyperactivity disorder (ADHD), eating disorders, and pain (Bönisch and Brüsss 
2006; Zhou 2004). Thus, the -conotoxins are important leads for the 
development of better drugs for the treatment of the above mentioned 
pathological conditions. For example, the -conotoxin, -MrIa is undergoing 
clinical trials for the treatment of pain. The divergent activity of fv1a as opposed 
to the -conotoxins, as shown in the intracranial injections of the peptides, and in 
the calcium imaging of DRG neurons, indicates that there is a possible new 
conotoxin family in the T-superfamily and that this family contains conotoxins with 
a unique set of biological and pharmacological activities. Moreover, the activities 
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of these peptides in the calcium imaging experiments are particularly interesting. 
The molecular mechanisms underlying these observed activities will be the 























Figure 2.1. Phylogenetic relationships in mollusk-hunting cone snails. The 
cone snail species from which conotoxins reported in this paper were isolated are 

































Figure 2.2. Purification of -Au1D. A) HPLC chromatogram showing the 
absorbance profile at 220 nm of crude C. aulicus venom fractionated on a 
preparative C18 column using a linear gradient of 1.3% B90/min at a flow rate of 
20 mL/min. The fraction marked by the arrow showed inhibitory activity against 
NET. B) Analytical HPLC chromatogram profile of the subfractionation of the 
active component in A. The subfractionation was performed using a linear 
gradient of 30% - 50% B90 for 20 min at a flow rate of 1 mL/min. The active peak 
is marked by an arrow. C) Analytical HPLC chromatogram profile showing the 
homogeneity of the active fraction in B. The HPLC experiment was done using 
















Figure 2.3. Purification of fv1a. A) HPLC chromatogram showing the 
absorbance profile at 220 nm of crude C. furvus venom fractionated on a semi-
preparative C18 column. The components were eluted using a gradient of 1.6% 
B90/min for 60 min at a flow rate of 4 mL/min. The HPLC peak marked by the 
arrow contains fv1a. B) Analytical HPLC profile of the subfractionation of the 
peak marked in A. The subfractionation experiment used a linear gradient of 1% 
B90/min starting at 10% B90 for 20 min. The arrow indicates the fraction 
containing fv1a. C) Analytical HPLC profile showing that fv1a has been purified to 
homogeneity. The gradient used to verify the purity of fv1a is the same gradient 

















Figure 2.4. Co-elution experiment of the native and synthetic -AuID and 
fv1a. The peptides were synthesized and folded as described in the 
“Experimental Procedures.” A) Analytical HPLC chromatogram profile showing 
the absorbance at 220 nm of the native -AuId (top), synthetic -AuId (middle) 
and a mixture of the native and synthetic -AuId (bottom). The co-elution 
experiment was performed using a 1%/min linear gradient of B90 starting at 30% 
B90 for 20 min at a flow rate of 1 mL/min. B) Analytical HPLC chromatogram 
profile showing the absorbance at 220 nm of the native FvIa (top), synthetic fv1a  
(middle) and a mixture of the native and synthetic fv1a (bottom). The coelution 
experiment was perfromed using a linear gradient of 10% - 30% B90 for 20 min 




















Figure 2.5. Activity of -AuID, -AoIC, and fv1a against human 
norepinephrine transporter (hNET) expressed in HEK-293 cells. The 
inhibitory activity of -AuID, and -AoIc against the human NET is dose-
dependent. IC50 values for -Ao1C and -Au1d are 2.6 ± 0.4 M and 0.7 ± 0.2 
M, respectively. The activity of fv1a against NET at 200 M is also shown. Each 
data point was normalized against 100% activity occurring in the absence of the 






































Figure 2.6. Sequence alignment of the precursors of fv1a, -AuID and -
MrIA. These three precursors display a very high degree of sequence similarity 
in the signal sequence as well as a conserved pattern of cysteine residues in the 
toxin region indicating that these conotoxins belong to the same conotoxin 
superfamily. The conotoxin -MrIa was previously shown to belong to the T-
superfamily (Mcintosh et al, 2000) hence fv1a and -AuId are also members of 





















































Figure 2.7. Comparison of the effects of fv1a and the -conotoxins on the 
response of DRG neurons to depolarization by 25 mM KCl. 25 mM KCl was 
consecutively applied at 7-min intervals into a culture of dissociated mouse DRG 
neurons. After the third KCl application, the DRG neurons were incubated with 
1.5 M of the conotoxins. The activity of the conotoxins is seen as the changes in 
peak height corresponding to fluxes of cytosolic calcium in the KCl pulse 
immediately following conotoxin incubation. fv1a partially inhibits the cytosolic 
calcium increase in 13.3 (±2.6)% of the cells whereas the -conotoxins cause an 
amplification of the calcium response of the cells upon KCl depolarization. The 
percentage of neurons affected by the -conotoxins are: -AoIC: 4.5 (±0.5)%; -











Table 2.1. T-superfamily conotoxins presented and discussed in this paper. 
 
Conotoxin Sequence Conus species Prey Reference 
-AuID  SVCCGYKLCFOC* C. aulicus mollusk This work 
-AoIC   RCCGYKMCHOC C. araneosus mollusk 
Gupta et al. 2010; This 
work 
-MrIA NGVCCGYKLCHOC C. marmoreus mollusk 
McIntosh et al. 2000; 
Balaji et al. 2000; 
Sharpe et al. 2001  
fv1a  GVCCAHTGCKOCP C. furvus mollusk This work 
*Indicates C-terminal amidation; O: hydroxyproline; Identical amino acids between the 
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FUNCTIONAL CHARACTERIZATION OF PRURICEPTORS  








 Itch is defined as an unpleasant sensation that causes the reflex to 
scratch. The sensation of itch known as pruriception is detected by neurons 
whose cell bodies are found in the dorsal root ganglion (DRG). Itch is classified 
as either histamine-dependent or histamine-independent. Here we showed three 
classes of neurons from the mouse dorsal root ganglion (DRG) that respond to 
histamine and chloroquine. Class A (His+) neurons respond to histamine alone, 
class B (CQ+) neurons respond to chloroquine alone, and class C (His+, CQ+) 
neurons respond to both histamine and chloroquine. The class A and class B 
cells are heterogeneous and can be divided based on the expression of TrpV1 
and TrpA1, respectively, whereas class C cells are more homogeneous in terms 
of Trpv1 and bradykinin receptor expression. Using different ligands for voltage-
gated sodium channels we have also identified expression of Nav1.7 and Nav1.8 
in the different cell classes of DRG neurons that are sensitive to the pruritogens 
histamine and chloroquine. 
 
Introduction 
 Each locus in the nervous system contains neurons with different set of 
properties (Franco and Müller 2013; Nelson et al. 2006; Sugino et al. 2006). 
Since a particular anatomical locus in the nervous system is involved in various 
physiological functions, it is expected that there exist a multitude of neuronal 
populations with varying patterns of ion channel and receptor expression in a 
given anatomical locus. The identification of these neuronal populations and the 
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corresponding constellation of ion channels and receptors expressed in these 
populations are important for the thorough understanding of their physiological 
function, and for monitoring changes in these populations as a function of ageing 
and the progression of pathological conditions. 
 The dorsal root ganglion (DRG) contains the cell bodies of neurons that 
send nerve projections into the periphery where they are activated by various 
chemical and mechanical stimuli. The activation of these nerves leads to different 
modes of somatosensation such as heat, cold, pain, and itch (Basbaum et al. 
2009; Delmas et al. 2011). Since DRG neurons can detect a variety of 
somatosensory modalities, it follows that the cell types in a population of DRG 
neurons is extremely complex.  It is estimated that there are >25 different cell 
types in DRG neurons (Teichert et al. 2012a). 
 One of the cell types of DRG neurons are the pruriceptors which detect 
itch and these cells are activated by pruritogens (itch-causing compounds) 
(LaMotte et al. 2013).   Itch is defined as an unpleasant sensation that causes 
the reflex to scratch (Tominaga and Takamori 2013; Wilson and Bautista 2013; 
Yosipovitch et al. 2003). Itch can be acute, for example, an itch caused by an 
insect bite or chronic itch like in the case of people who suffer from atopic 
dermatitis (Ikoma  et al. 2006; Paus  et al. 2006). Severe cases of chronic itch 
greatly reduce the quality of life of people who suffer from the condition (Carr et 
al. 2013; Kini et al. 2011; Yosipovitch et al. 2003). Majority of itch conditions are 
associated with pathologies in the skin, however, itch can also be a symptom of 
organ pathologies such as some forms of liver disease or kidney failure (Belghiti 
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et al. 2013; Combs et al. 2015; Kremer et al. 2014; Mettang and Kremer 2015). 
 Itch is classified into two types: histamine-dependent itch and histamine-
independent itch (Roberson et al. 2013; Akiyama et al. 2014). Histamine induces 
itch primarily through the activation of the H1R receptor (Shim and Oh 2008; 
Rossbach et al. 2011). Chloroquine an antimalaria drug, acting through the 
Mrgpra3 receptor induces histamine-independent itch (Liu et al. 2009; Wilson et 
al. 2011). There is limited information about mechanisms involved in the 
sensation of itch especially those mediated by the histamine-independent 
pathway (Jeffry et al. 2011). The identification and characterization of neuronal 
populations that respond to pruritogens are one of the important steps needed for 
a clearer understanding of the mechanisms that mediate itch. 
 Here we report the identification of three major subclasses of pruriceptors 
in the mouse DRG neurons. Class A responds to histamine (His+), class B 
responds to chloroquine (CQ+), and class C responds to both histamine and 
chloroquine (His+, CQ+). These pruritogen-sensitive cell classes are mostly 
small to medium diameter neurons and they make up a very small percentage of 
neurons in the DRG. Results from our experiments revealed the expression of 
receptors that are associated with nociception in the different subpopulation of 
pruritogens. We also report on the expression of Nav1.7 and Nav1.8 in these cell 
classes. Our research has identified cellular markers that can refine the definition 
of the pruriceptor class. These molecular markers serve an important role in the 
mechanistic understanding of itch. Moreover, the molecules identified in this 
research are potential therapeutic targets for the treatment of itch.  
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Materials and methods 
Calcium imaging.  The protocols for experiments using mice were 
approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of Utah. Methods for the culture of dorsal root ganglion (DRG) neurons 
have been described previously.  Briefly, lumbar DRG’s from adult CD1 mouse 
expressing green-fluorescent protein (GFP) conjugated to the calcitonin gene-
related peptide (CGRP) were pooled and the cells dissociated and cultured 
overnight. FURA-2-AM dye was allowed to permeate the cells for 1 h. During the 
experiment the dye was excited alternately with 340- and 380-nm light and the 
emission from both excitations was monitored at 510 nm. The ratio of 
fluorescence intensity (340/380) is a measure of the cytosolic calcium. Results 
from these experiment is calcium imaging graph where the Y-axis represent the 
340/380 ratio and the X-axis represent time in minutes. Specific times when a 
pharmacological agent is added are marked by arrows. Horizontal bars mark 
duration of the incubation of cells with the specified pharmacological agent. 
Cellular profiling of histamine and chloroquine sensitive neurons. 
The cell culture was first depolarized by the addition of 30 mM KCl in 1x DRG 
observation solution (145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 1 mM 
sodium citrate, 10 mM glucose, 10 mM HEPES, and 1X penstrep) to identify 
neurons. After depolarization, the cells were challenged by the sequential 
application of different pharmacological agents every 5 min. The compounds 
were added in the following sequence: histamine (100 mM), chloroquine (1 mM), 
4 ⁰C bath, bradykinin (10 mM), menthol (400 mM), AITC (100 mM), and capsaicin 
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(300 nM). Histamine, chloroquine, 4 ⁰C bath and bradykinin were incubated with 
the cells for 30 s while the other reagents were incubated with the cells for 10 s. 
All reagents were purchased from Sigma (St. Louis, MO, USA). A summary of 
the reagents used in these experiments are shown in Table 4.1. 
Voltage-gated sodium channels in His+, Caps+ and CQ+, AITC+ 
neurons.  The experiment was started by the addition of 100 M histamine. The 
cells were then washed and after 5 min, 1 mM chloroquine was added to the 
cells. After the chloroquine addition, the cells were depolarized three times with 
20 mM KCl at 5-min-intervals. After the third KCl pulse, 1 M tetrodotoxin (TTX) 
in 1X DRG observation solution was added to the cells. After 4 min this solution 
was replaced with another solution containing 20 M veratridine and 1 M TTX. 
After 1 min the cells were depolarized with a solution containing 20 mM KCl, 20 
M veratridine, and 1 M TTX. The cells were then washed and depolarized 
twice with 20 mM KCl every 5 min. Throughout this phase of the experiment, the 
cells were incubated with 1 M TTX. After these depolarizations, the 1 M TTX 
solution was replaced 10 M -PIIIA. After 4 min, the -PIIIA solution was 
replaced and the cells incubated for 1 minute with a solution containing 20 M 
veratridine, and 10 M -PIIIA. After 1 min, the cells were depolarized by a 
solution containing 20 mM KCl, 20 M veratridine, and 10 M -PIIIA. The cells 
were finally depolarized twice every 5 min while maintaining the -PIIIA 
concentration. After the final depolarization, menthol, AITC, and capsaicin were 
sequentially added to the cells every 5 min. Relevant information about the 




 Dorsal root ganglion (DRG) neurons from CD1 mouse heterologously 
expressing green fluorescent protein (GFP) marker conjugated to the calcitonin 
gene related peptide (CGRP) were dissociated and cultured overnight. CGRP is 
a marker for peptidergic nociceptors (McCoy et al. 2013), hence, neurons 
displaying the green fluorescence of GFP belong to the peptidergic nociceptor 
class. The cells were also stained with antibodies against isolectin B4 (IB4) to 
identify neurons that belong to the nonpeptidergic nociceptor class (Franck et al. 
2011). A total of 5099 neurons were examined based on their responses to 
various challenges in the calcium imaging experiments. Histamine and 
chloroquine were used to identify the putative pruriceptors. The cells were also 
challenged with 4 ⁰C bath as well as bradykinin, menthol, AITC, and capsaicin to 
determine whether the pruriceptor class also coexpresses the receptors of these 
challenge compounds. Another experiment determined the expression of 
voltage-gated sodium channel using veratridine, tetrodotoxins (TTX) and the 
conotoxin -PIIIA. The compounds used in these experiments and their 
corresponding molecular targets are listed in Table 4.1.  
The pruriceptors comprise a very small percentage of neurons in the 
DRG.  Histamine and chloroquine were used to identify the cells expressing the 
histamine and chloroquine receptor. Activation of the H1R receptor by histamine 
and the MrgprA3 receptor by chloroquine was shown to induce symptoms 
associated with itch (Shim and Oh 2008; Rossbach et al. 2011; Liu et al. 2009; 
Wilson et al. 2011). Application of 100 M histamine and 1 mM chloroquine in the 
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same experiment elicited a robust increase in cytosolic calcium in a small 
number of neurons in the experiment. Our experiments showed predominantly 
divergent expression of the histamine and chloroquine receptors. Cells that 
respond to histamine alone belong to class A (His+ cells) whereas cells that 
respond to chloroquine are class B cells (CQ+ cells). There is, however, a very 
small number of neurons belonging to class C (His+, CQ+) cells that express the 
receptors for both histamine and chloroquine. Experiments conducted on 5099 
neurons prepared from three adult mice showed that 3% of neurons belong to 
class A (His+),  9% of neurons are in class B (CQ+), and 1% of neurons are 
class C (His+, CQ+ cells) (Figure 4.1B). Interestingly, these cell classes 
responding to pruriceptors contain both peptidergic and nonpeptidergic 
nociceptors. The class A (His+), class B (CQ+), and class C (His+, CQ+) classes 
contains 30%, 39%, and 32% peptidergic nociceptors, respectively. The 
nonpeptidergic neurons comprise 53% of the class A (His+) cells, 61% of the 
class B (CQ+) cells, and 43% of the class C (His+, CQ+) cells. Representative 
calcium imaging traces of cells in these pruriceptor classes are shown in Figure 
4.1A. 
The pruriceptors also express markers for nociceptive neurons. 
Bradykinin (bradykinin receptor agonist), allyl isothiocyanate (AITC) (TrpA1 
agonist), and capsaicin (TrpV1 agonist) are markers for nociceptive neurons 
(Cayla et al. 2012; Rashid et al. 2004; Miyamoto et al. 2009; Viana 2016; Julius 
2013). Further, it was shown that TrpV1 is required for histamine-dependent 
(Shim et al. 2007) itch while TrpA1 is required for histamine-independent itch 
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(Wilson et al. 2011). Individual applications of bradykinin, AITC, and capsaicin 
elicited a response in a subset of cell populations that are sensitive to histamine 
and chloroquine. 51.0 ± 4.2% of cells in class A respond to capsaicin while the 
remainder of the cells are insensitive to capsaicin. In class B cells (CQ+), 50.0 ± 
2.4% respond to AITC while the rest of the cells in class B did not respond to 
AITC. Given these results, the class A cells (His+) could be further subdivided 
into the His+, Caps+ subclass, and the His+, Caps- subclass while the class B 
cells (CQ+) could be further subdivided into the CQ+, AITC+ subclass, and CQ+, 
AITC- subclass. Since TrpV1 the capsaicin target is required for histamine-
dependent itch while the AITC target TrpA1 is required for histamine-independent 
itch, it is interesting that not all the cells in class A (His+) respond to capsaicin 
and not all cells in class B (CQ+) respond to AITC.  Thus, the His+, Caps+ cells 
in class A and the CQ+, AITC+ cells in class B mediates itch through the 
previously identified TrpV1-dependent (histamine-dependent) and TrpA1-
dependent (histamine-independent) mechanisms, respectively. Surprisingly the 
class C cells (His+, CQ+) cells are more homogeneous than either of the cells in 
class A or class B.  In class C cells (His+, CQ+), 73.0 ± 7.4% respond to 
bradykinin and 92 ± 4.5% of these cells also respond to capsaicin. These data 
suggest that class C cells mediate itch through the histamine-dependent 
mechanism. Although the possibility that class C cells mediate itch through the 
histamine-indpendent mechanism cannot be ignored at this point.  
Voltage-gated sodium channels in His+, Caps+ cells, and  CQ+, 
AITC+ cells.  Combinations of pharmacological agents were used to specifically 
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activate voltage-gate sodium channel (VGSC) isoforms in the different classes of 
pruriceptors.  These experiments were performed by the sequential application 
into the DRG neurons of veratridine and tetrodotoxin (TTX) and veratridine and 
the conotoxin -PIIIA. Veratridine is a compound that activates voltage-gated 
sodium channel while TTX and -PIIIA selectively inhibit specific VGSC isoforms. 
The combination of TTX and veratridine inhibits TTX-sensitive VGSC and 
activate TTX-resistant VGSC while the combination of veratridine and -PIIIA will 
only activate Nav1.7 and TTX-resistant VGSC and inhibit the rest of the neuronal 
TTX-sensitive VGSC. Previously, Teichert et al. (2012b) showed that the 
combination of TTX and veratridine activates Nav1.8. Thus, the application 
veratridine and TTX will identify Nav1.8 while the application of veratridine and -
PIIIA will identify Nav1.8 and Nav1.7. Sample calcium imaging traces for these 
experiments are shown in Figure 4.2A. 
 Analysis of the experiments showed that a percentage of the cells in class 
A, class B, and class C showed amplification of the cytosolic calcium 
concentration when depolarized by KCl in the presence veratridine and TTX 
suggesting the expression of Nav1.8.  Depolarizing the cells in the presence of 
veratridine and -PIIIA elicited a higher increase in cytosolic calcium in a percent 
of cells in each class when compared to the previous depolarization in the 
presence of veratridine and TTX suggesting the expression of Nav1.7.  
Quantifying the results from these experiments showed that 45.7 ± 5.8% and 
72.3 ± 2.3% of cells in class A express Nav1.8 and Nav1.7, respectively. In class 
B cells, 52.0 ± 2.9% express Nav1.8 and 64.0 ± 7.2% express Nav1.7. In class C 
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cells, 36.7 ± 5.9% express Nav1.8 and 85.0 ± 4.5% express Nav1.7. These 
results are shown in Figure 4.2B. 
 
Discussion 
 Constellation pharmacology is an experimental paradigm that uses 
calcium imaging to determine the expression of ion channels and receptors in a 
particular cell class. The identification of ion channel and receptor expression is 
achieved by the sequential application of pharmacological agents called 
challenge compounds to a culture of cells. The receptor agonist challenge uses 
specific receptor agonists to elicit a response from the cells while the membrane 
potential challenge uses ligands of voltage-gated ion channels which could either 
activate or inhibit the channels when the membrane is depolarized. The 
application of different challenge compounds into a culture of dorsal root ganglion 
(DRG) neurons elicits a wide array of responses. Cells that have the same 
response profile are classified into specific cell classes/types. Using the 
constellation pharmacology paradigm, Teichert et al. (2012b) has successfully 
identified subclasses of neurons in the mouse DRG. 
 Here we used constellation pharmacology to identify cellular subclasses 
that are responsive to the pruritogens histamine and chloroquine. Histamine 
defines histamine-dependent itch whereas chloroquine defines histamine-
independent itch.  Considering that there are two general classifications of itch 
we designed experiments to test whether different cell populations are sensitive 
to histamine and chloroquine. Our experiments revealed three cell classes that 
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respond to the pruritogens. One class we call class A respond to histamine 
alone, the class B cells respond to chloroquine alone, and the class C respond to 
both histamine and chloroquine. Interestingly, the pruritogen responsive 
population contains cells that are either positive for CGRP and/or IB4, suggesting 
that these populations contain cells belonging to the peptidergic nociceptor and 
nonpeptidergic nociceptor classes. These results indicate the heterogeneity of 
the cellular classes in the DRG that are sensitive to the pruritogens.  
 Cell classes A and B have an added level of heterogeneity in terms of the 
expression of Trp channels previously shown to be important for histamine-
dependent and histamine-independent itch. Class A cells can be further 
subdivided into the capsaicin sensitive (His+, Caps+) and capsaicin insensitive 
(His+, Caps-), whereas the class B cells can be further divided into the AITC 
sensitive (CQ+, AITC+) and AITC insensitive (CQ+, AITC-) subclasses. 
Research has previously shown that TrpV1 the capsaicin receptor is required for 
histamine-dependent itch while the AITC receptor TrpA1 is required for 
histamine-independent itch (Shim et al. 2007; Wilson et al. 2011). These results 
indicate two possibilities in terms of the cell classes that detect itch. One 
possibility is that only the His+, Caps+ and CQ+, AITC+ subclasses are the 
pruriceptors while the other subclasses His+,  Caps- and CQ+, AITC- are 
possibly involved in other modes of somatosensation. Another possibility is that 
all the His+ and CQ+ cells are pruriceptors, however, the His+, Caps- class and 
the CQ+, AITC- cells mediate itch in a mechanism that does not require TrpV1 
and TrpA1, respectively.  
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Interestingly, the class C cells which comprise the smallest population of 
pruritogen-sensitive neurons is generally homogeneous. The majority of the cells 
in this class express the bradykinin receptor (BkR) and TrpV1. Thus, class C 
cells can mediate itch through the histamine-dependent mechanism that requires 
TrpV1. The expression of the BkR in this class is unexpected considering that 
bradykinin receptor is associated with nociceptors. However, reports showed that 
bradykinin the ligand for BkR is a pruritogen when applied to skin lesions in 
atopic dermatitis (AD) (Hosogi et al. 2006), thus, in atopic dermatitis, BkR 
mediates itch. The data presented by Hosogi et al. (2006) together with our 
experimental results suggest that class C cells is the potential pruriceptor that is 
involved in the itching caused by bradykinin in AD. Moreover, these data suggest 
that inhibitors of BkR can potentially be explored for the treatment of itch in atopic 
dermatitis. 
 Membrane potential challenge was used to identify the expression of 
voltage-gated sodium channels (VGSC) in the cell classes identified in this 
research. A combination of VGSC agonist and antagonist elicited responses 
indicative of the expression Nav1.8 and Nav1.7. The Nav1.8 expression was 
determined from the response of the cells upon depolarization by KCl in the 
presence of veratridine and tetrodotoxin (TTX). In the same experiment, TTX and 
the conotoxin -PIIIA (10 M) were applied after washing veratridine. The 
concentration of -PIIIA used in these experiments would inhibit neuronal 
VGSC’s except Nav1.7, therefore, the increase in cytosolic calcium concentration 
is a result of the activation of both Nav1.8 and Nav1.7. Thus, the higher increase 
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in cytosolic calcium concentration in response to the application of -PIIIA and 
TTX when compared to the application of veratridine and TTX suggest the 
expression of Nav1.7.  
Results from the experiment showed that all the cell classes 
predominantly express Nav1.7. Class C cells (His+, CQ+) has the largest 
percentage of cells expressing Nav1.7 class B cells has lowest Nav1.7 
expression. Nav1.8 is not expressed to the same extent as Nav1.7. The highest 
Nav1.8 expression is found in class B cells while class C cells have the least 
Nav1.8 expression. The broad expression of Nav1.7 across all cell classes we 
have identified in this research suggests the involvement of Nav1.7 in both the 
histamine-dependent and histamine-independent itch. Our conclusion regarding 
the involvement of Nav1.7 in itch is in agreement with the experimental results by 
Devigili et al. (2014) which showed that a gain of function mutation in Nav1.7 
causes paroxysmal itch. Our data further suggest that specific inhibitors of 
Nav1.7 are potential drugs for the treatment of both histamine-dependent and 
histamine-independent itch. Lee et al. (2014) has shown that the inhibition of 
Nav1.7 by a monoclonal antibody specific to Nav1.7 attenuates both histamine-
dependent and histamine-independent itch. Presumably the monoclonal antibody 
targets Nav1.7 which is predominantly expressed in the cell classes we have 
identified here. 
In this research we have identified classes of DRG neurons that are 
responsive to the pruritogens histamine and chloroquine. The three classes of 
cells we have identified in this research mirror the complexity of pruriception in 
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which different mechanisms were shown to mediate itch. The class A and class 
C cells which are histamine sensitive presumably mediates itch through the 
histamine dependent mechanism, whereas class B and class C cells mediate itch 
through the histamine-independent mechanism. 
Our data point to an underlying complexity in an already complex mode of 
somatosensation which is itch. Approximately 50% of the cells in classes A and B 
express the receptors shown to be required for itch. Thus, only half of cells in 
these cell classes mediate itch under the canonical TrpV1- and TrpA1-mediated 
mechanism. However, Han et al. (2013) showed that MrgprA3-expressing 
neurons are a labelled line specific for itch. Moreover TrpV1 and TrpA1 knock-out 
did not completely abolish both histamine-dependent and histamine-independent 
itch, respectively (Shim et al. 2007; Wilson et al. 2011). These data suggest that 
there is an unknown mechanism of sensing itch that is independent of TrpV1 and 
TrpA1. Our research has identified the possible cell classes that mediate itch in a 
mechanism that neither requires TrpV1 in histamine-dependent itch nor TrpA1 in 
histamine-independent itch.  
Class C cells express both the histamine receptor and MrgprA3. This cell 
class predominantly expresses Trpv1, thus, cells in this class mediate itch in a 
histamine-dependent mechanism that requires TrpV1. Interestingly, a small 
percent of cells in this class expresses TrpA1, thus, only these cells mediate 
histamine-independent itch that requires TrpA1. However, chloroquine was 
shown to sensitize TrpV1 (Than et al. 2013) suggesting that itch could also be 




 The tailored therapeutic strategy for targeting specific neuronal subtypes 
involved in pathologies is one of the immediate applications of constellation 
pharmacology. This is illustrated by the potential use of bradykinin receptor 
antagonist for the treatment of itch in atopic dermatitis.  Another application of 
classifying cell classes and cataloging ion channel and receptor expression is the 
ability to monitor changes in these cell classes as a function of disease or 
ageing. Our results for the different pruriceptor class serve as a baseline for 
comparison of the changes in these cell classes. Importantly, we have identified 
cell classes such as the capsaicin negative cells in class A and AITC negative 
cells in class B that potentially mediate itch in a mechanism that does not require 
TrpV1 and TrpA1. Future research should focus on these cell classes for a more 













Figure 4.1. Responses of DRG neurons to the application of histamine and 
chloroquine and other challenge compounds. A) Sample calcium imaging 
traces showing the response profile of the three major classes of neurons 
responding to the pruritogens histamine and chloroquine. Each trace represents 
a single cell in the experiment. The Y-axis represents the ratio of the emission at 
340 nm and 380 nm (340/380) while the X-axis represents time and the specific 
time point where a challenge compound is added is marked by an arrow. Each 
upward deflection in the graph represents a response to a specific challenge 
compound. The top 3 panels represents the class A (His+) cells, the middle three 
panels represent the class B (CQ+) cells, and the bottom 3 panels represent the 
class C (His+, CQ+) cells. These traces also shown the response of the cells to 
capsaicin, AITC and bradykinin B) Quantification of the percentage of cells in 
each major pruritogen-sensitive population responding to a specific challenge 
compound. The experiments showed that class A (His+), class B (CQ+), and 
class C (His+,CQ+) cells comprise 3%, 9% and 1% respectively of the total DRG 
neuron population. The percentage cells that do not respond to histamine and 

























    
















Figure 4.2. Voltage-gated sodium channel (VGSC) expression in the class A 
(His+) cells, class B (Caps+) cells and in class C (CQ+, AITC+) cells. A) 
Sample calcium imaging trace for the experiment to identify expression of Nav1.7 
and Nav1.8 in the different classes of prurifeptors. The top panel show 
representative trace of the class A (His+) cells, the middle panel shows a 
representative trace of the class B (CQ+) cells and the bottom panel shows a 
representative trace of the class C (His+, CQ+) cells. The cells were depolarized 
by the application of 20 mM KCl. The application of TTX and veratridine amplifies 
the response from TTX-resistant Nav1.8 VGSC while the application of TTX and 
-PIIIA amplifies the response from Nav1.8 and Nav1.7. The time intervals when 
TTX and -PIIIA is incubated with the cells is marked by the solid black line while 
the time interval of veratridine incubation is marked by the solid gray line. The 
results of the experiments are quantified in B. 72.3 ± 2.3% of cells in class A 
express Nav1.7 while 45.7 ± 5.8% express Nav1.8. In class B cells, 64.0 ± 7.2% 
express Nav1.7 and 52.0 ± 2.9% express Nav1.8. In class C cells, 85.0 ± 4.5% of 
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Table 4.1. Challenge compounds used in experiments conducted in this 
research. 










Menthol Me/M TrpM8 400 M 
Allyl 
isothiocyanate 
AITC/A TrpA1 100 M 
Capsaicin Caps/C TrpV1 300 nM 
Tetrodotoxin TTX VGSC 1 M 
Veratridine Ver VGSC 20 M 
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In this research, novel vertebrate-active conotoxins were identified from 
cone snail clades with very limited toxinological information. These conotoxins 
were discovered using the norepinephrine transporter (NET) uptake assay and 
calcium imaging. These assays were never before used for conotoxin discovery. 
Chapter 2 describes conotoxins purified from the venom of cone snails from 
different mollusk-hunting clades using the NET uptake assay. Chapter 3 
describes conotoxins purified using calcium imaging and identified from a clade 
of worm-hunting cone snails. The major driving force for the efforts to discover 
novel conotoxins is the research and therapeutic applications of these 
compounds. Chapter 4 described a research project where a conotoxin was one 
of the pharmacological compound used to identify ion channels and receptors 
expressed by a small population of dorsal root ganglion (DRG) neurons that are 
sensitive to pruritogens (itch-causing compounds). 
 
Pharmacologically distinct peptides in the T-superfamily  
The conotoxins described in Chapter 2 were all purified from mollusk-
hunting cone snails and belong to the T-superfamily. These conotoxins share the 
same pattern of disulfide bonds, however, the biological activities of these 
conotoxins in mice indicate they belong to different pharmacological families. 
Two of these conotoxins -AoIC and -AuID inhibit the norepinephrine 
transporter (NET) and belong to the -conotoxin family. The conotoxin fv1a does 
not inhibit NET, however, this peptide is active in our assays. fv1a partially 
inhibits the cytosolic flux of calcium in a population of dorsal root ganglion (DRG) 
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neurons upon depolarization by KCl and elicits in vivo a hyperactive phenotype 
upon intracranial (IC) injection in mice.  
 The activity of -AoIC and -AuID against NET has medical significance 
since NET has been implicated in various neurological disorders (Bönisch and 
Brüsss 2006; Zhou 2004). It is important to note at this point that the first -
conotoxin discovered -MrIA from Conus marmoreus, has gone through phase II 
clinical trial for the treatment of pain (Brust et al. 2009; Green et al. 2014), thus, 
the -conotoxins reported in this dissertation can also be explored for their 
application in the treatment of pain. The analgesic effect of NET inhibitors is 
shown to involve the activation of 2-adrenergic receptors in the descending pain 
pathway (Hajhashemi et al. 2014; Hall et al. 2011). 
 The conotoxin fv1a from Conus furvus (Calibanus clade) (Puillandre et al. 
2014) is homologous to the the -conotoxins, however, this conotoxin does not 
inhibit NET. fv1a is biologically active in vivo in mice upon intracranial (IC) 
injection and displays partial inhibition of the cytosolic calcium increase in DRG 
neurons upon depolarization by KCl in calcium imaging experiments. 
Experiments conducted in this research indicate that fv1a is pharmacologically 
distinct from the -conotoxins, hence, fv1a belongs to a different conotoxin 
family.  
 The conotoxins -AoIC, -AuID and fv1a reported here and together with 
the previously characterized -MrIa allowed for the identification of amino acids 
important for the inhibitory activity of the -conotoxins against NET. Analysis of 
the sequence revealed that the amino acids flanked by the second and third 
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cysteines are conserved among the -conotoxins and highly divergent in fv1a 
(Figure 5.1). Thus, the amino acids -GYKL- are important for NET inhibition. 
Conservative substitution in these amino acids does not appear to be crucial for 
activity against NET. For example, the substitution of  leucine with a methionine 
in -AoIC did not affect the activity of -AoIC to inhibit NET.  
 The discovery of related conotoxins with varying degrees of potency 
toward NET is important since these conotoxins can be used to identify the 
mechanism of NET inhibition. Knowing how these conotoxins inhibit NET can 
lead to the design of ligands that 1) would target NET with very high specificity 
and potency, and 2) have fewer side effects in cases they are used as drugs. For 
example, sequence comparison among the -conotoxins indicates that the 
leucine to methionine substitution in -AoIC appears to increase the potency of 
-AoIC to inhibit NET. Thus, it appears that a bigger more hydrophobic amino 
acid in this position would result to a more potent ligand that inhibits NET.  
 
Glycine-rich conotoxins in the O1-superfamily 
The O1-superfamily currently contains the most medically important 
conotoxin, -MVIIA. -MVIIA is a drug sold under the name Ziconotide (Prialt) for 
the treatment of pain. The inhibitory activity of this conotoxin against the voltage-
gated calcium channel isoform Cav2.2 is the mechanism for its analgesic activity 
(Miljanich 2004). The O1-superfamily also contains conotoxins that target 
voltage-gated potassium channels (-conotoxins) (Shon et al. 1998) and voltage-
gated sodium channels (- and O-conotoxins) (Bulaj et al. 2000; McIntosh et al. 
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1995). Examples of these conotoxin families are given in Table 5.1. It is to be 
noted that most of these conotoxins were identified from the venom of fish-
hunting cone snails. However this table does not imply that only fish-hunting 
cone snails are sources of vertebrate-active conotoxins belonging to the O1-
superfamily. The worm-hunting cone snails comprise the largest group in Conus 
thus, worm hunters potentially hold a tremendous wealth of vertebrate-active 
conotoxins in the O1-superfamily. 
 The conotoxins described in Chapter 3 all belong to the O1-superfamily, 
and they were all identified from the Virgiconus clade of worm-hunting cone 
snails. The first conotoxin identified from this clade is vi6a from Conus virgo. vi6a 
causes a partial inhibition of the increase in cytosolic calcium in response to 
depolarization of DRG neurons by KCl in calcium imaging experiments. 
Intracranial (IC) and intraperitoneal (IP) injection of vi6a into young mice (17 – 21 
days old) elicit hyperactivity. 
  A striking feature of vi6a is the unusual abundance of glycine residues. 
vi6a has 26 noncysteine residues and 11 of these 26 amino acids are glycines. A 
screen of the mRNA transcripts isolated from the venom ducts of Conus virgo, 
Conus terebra, and Conus kintoki which are also members of the Virgiconus 
clade revealed homologous conotoxins that are equally glycine-rich. Surprisingly, 
two glycine-rich conotoxins were further identified from Conus virgo. In total, 3 
glycine-rich conotoxins were identified from C. virgo, two from C. terebra, and 
one from C. kintoki. C. virgo and C. terebra are shallow water species whereas 
C. kintoki is a deep water species, thus, it appears that the glycine-rich 
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conotoxins are expressed by members of the Virgiconus clade across a wide 
range of marine habitats.  
 The novel conotoxins described in this research appear to be distinct from 
previously described conotoxins in the O1-superfamily. A very obvious difference 
is the abundance of glycine residues. Moreover, the behavioral phenotype 
elicited by vi6a upon IC injection is also distinct from that of the other O1-
superfamily conotoxins. As previously mentioned, intracranial (IC) injection of 
vi6a into mice causes hyperactivity whereas IC injection of -MVIIA causes 
shaking (Olivera et al. 1987), IC injections of -, -conotoxins cause tetanic 
paralysis (Shon et al. 1995; Olivera and Cruz 2001) and IC injections of O-
conotoxins causes ataxia and/or reversible coma (McIntosh et al. 1995). It 
appears that the family of glycine-rich conotoxins reported here is 
pharmacologically different from previously described O1-superfamily conotoxins. 
This conclusion is supported by preliminary results based on the effect of vi6a in 
mice upon IC injection. 
 
Pruritogen-sensitive neurons in the mouse dorsal root ganglion (DRG) 
The dorsal root ganglion (DRG) contains cell bodies of a diverse 
population of sensory neurons that when activated by various chemical and 
mechanical stimuli detect different somatosensory modes such as pain, cold, 
heat, and itch (Basbaum et al. 2009; Delmas et al. 2011). The different 
somatosensory modes detected by the DRG neurons point to the heterogeneity 
of the cell populations in this particular locus. It is estimated that there are >25 
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distinct cell populations in the DRG (Teichert et al. 2012). 
 Chapter 4 describes populations of cells in the DRG that respond to 
pruritogens (itch-causing compounds). These populations comprise a very small 
percentage of neurons in the DRG, however, they can still be further divided into 
three subpopulations. One population responds exclusively to histamine (Class 
A), another population responds exclusively to chloroquine (Class B), and a third 
and very small population respond to both histamine and chloroquine (Class C). 
 Our experiments revealed that the class C population (His+, CQ+) is 
generally homogeneous in terms of TrpV1 and bradykinin receptor (BkR) 
expression with TrpV1 and BkR expressed by 92 ± 4.6% 73 ± 7.4% of the cells in 
this population, respectively. Since this class expresses the histamine receptor, 
the high percent of TrpV1 expression in this population is expected since 
previous research has shown that TrpV1 is required for histamine-dependent itch 
(Shim and Oh 2007). Unexpectedly, only 14 ± 5.7% of the cells in class C 
population (His+, CQ+) express TrpA1 considering that all class C cells express 
the chloroquine receptor MrgprA3 which was reported to require TrpA1 for 
histamine-independent itch (Liu et al. 2009; Wilson et al. 2011). Thus, our data 
suggest that class C cells can signal itch through the histamine-dependent 
pathway. Although the possibility that class C cells can mediate histamine-
independent itch cannot be ignored at this point. 
 The high expression of the BkR in class C cells (73 ± 7.4%) is unexpected 
since BkR has been traditionally associated with nociceptors and not 
pruriceptors. However, it was shown that application of bradykinin the ligand for 
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BkR into atopic dermatitis (AD) lesion causes severe itching (Hosogi et al. 2006). 
This result and our data suggest that class C cells mostly mediate the itching 
caused by bradykinin in atopic dermatitis. Moreover, these data suggest that 
inhibitors of BkR are potential drugs for the treatment of itch in atopic dermatitis. 
 Class A (His+) and class B (CQ+) are not as homogeneous as the class C 
cells. Only 51 ± 4.2% of class a cells express TrpV1 and 50 ± 2.4% of class B 
cells express TrpA1. Thus, approximately half of class A and class B cells detect 
itch using the Trpv1-dependent (histamine-dependent itch) and TrpA1-dependent 
(histamine-independent) mechanism, respectively. However, it is interesting to 
note that Han et al. (2012) showed that MrgprA3 expressing cells are a specific 
labelled line for itch. Further Wilson et al. (2011) reported that the knockout of 
TrpA1 did not completely abolish itch caused by chloroquine. Thus, our data 
indicate the possibility that the non-TrpA1 expressing cells in the class B 
population could also mediate itch possibly in a mechanism that does not require 
TrpA1. Shim et al. (2007) showed that mice lacking TrpV1 has significantly 
reduced itching compared to wild type mice when injected with histamine. 
However, knocking out TrpV1 did not completely abolish itch. Thus, the TrpV1 
negative cells in class A could possibly mediate itch in a TrpV1-independent 
mechanism. 
 
Future research  
This research has discovered novel conotoxins that are active in mice. 
Further, this research also discovered different classes of neurons in the mouse 
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DRG that are responsive to the pruritogens histamine and chloroquine. The 
following research projects build on the results obtained in this thesis: 
1) Identify the molecular targets of fv1a and vi6a. 
2) Screen the venom of mollusk-hunting cone snails for peptides 
homologous to the -conotoxins and determine whether these peptides 
are pharmacologically distinct from -conotoxins. 
3) Explore the venom of worm-hunting cone snails from other clades for 
the expression of O-superfamily conotoxins and identify the biological 
activity and pharmacology of these conotoxins. 
4) Develop novel bioassays for the identification of vertebrate-active 
conotoxins from the venom of cone snails.  
5) Determine whether TrpV1 negative and TrpA1 negative cells in classes 
A and B mediate itch and identify the mechanism in which these cells 












Figure 5.1. Sequence alignment of T-superfamily conotoxins from mollusk-
hunting cone snails. Note that the amino acids in loop 1 between Cys2 and 
Cys3 are highly conserved among the conotoxins whereas these amino acids are 
highly divergent in fv1a. A conservative substitution of leucine to methionine in c-













































Prey  Sequence  References 
-MVIIA  C. magus fish CKGKGAKCSRLMYDCCTGSCRSGKC* 
Olivera et al. 
1987 
-PVIIA C. purpurascens fish CRIONQKCFQHLDDCCSRKCNRFNKCV 
Shon et al. 
1998 
-SVIE C. striatus fish DGCSSGGTFCGIHOGLCCSEFCFLWCITFID 
Bulaj et al. 
2001 
O-MrVIB C. marmoreus mollusk ACSKKWEYCIVPILGFVYCCPGLICGPFVCV 
McIntosh et al. 
1995 








Basbaum AI, Bautista DM, Scherrer G, Julius D. 2009. Cellular and molecular 
mechanisms of pain. Cell 139(2): 267-284. 
 
Bönisch H, Brüss M. 2006. The norepinephrine transporter in physiology and 
disease. Handb Exp Pharmacol. 175: 485-524. 
 
Brust A, Palant E, Croker DE, Colless B, Drinkwater R, Patterson B, Schroeder 
C, Wilson D, Nielsen CK, Smith MT, Alewood D, Alewood PF, Lewis RJ. 2009. -
conopeptide pharmacophore development: toward a novel class of 
norepinephrine transporter inhibitor (Xen2174) for pain. J Med Chem. 52(22): 
6991 – 7002. 
 
Bulaj G, Dela Cruz R, Azimi-Zonooz A, West P, Watkins M, Yoshikami D, Olivera 
BM. 2001. -conotoxin structure/function through a cladistics analysis. 
Biochemistry 40(44): 13201-13208. 
 
Delmas P, Hao J, Rodat-Despoix L. 2011. Molecular mechanisms of 
mechanotransduction in mammalian sensory neurons. Nat Rev Neurosci. 12(3): 
139-153. 
 
Green BR, Bulaj G, Norton RS. 2014. Structure and function of -conotoxins, 
peptide based sodium channel blockers with analgesic activity. Future Med 
Chem. 6(15): 1677 – 1698. 
 
Hajhashemi V, Banafshe HR, Minaiyan M, Mesdaghinia A, Abed A. 2014. 
Antinociceptive effects of venlafaxine in a rat model of peripheral neuropathy: 
role of alpha2-adrenergic receptors. Eur J Pharmacol. 738: 230-236. 
 
Hall FS, Schwarzbaum JM, Perona MT, Templin JS, Caron MG, Lesch KP, 
Murphy DL, Uhl GR. 2011. A greater role for the norepinephrine transporter than 
the serotonin transporter in murine nociception. Neuroscience 175: 315-327. 
 
Han L, Ma C, Liu Q, Wang HJ, Cui Y, Tang Z, Kim Y, Nie H, Qu L, Patel KN, Li Z, 
McNeil B, He S, Guan Y, Xiao B, LaMotte RH, Dong X. 2012. A sobpopulation of 
nociceptors specifically linked to itch. Nat Neurosci. 16(2): 174-182. 
 
Hosogi M, Schmelz M, Miyachi Y, Ikoma A. 2006. Bradykinin is a potent 
pruritogen in atopic dermatitis: a switch from pain to itch. Pain 126(1-3): 16-23.  
 
Liu Q, Tang Z, Surdenikova L, Kim S, Patel KN, Kim A, Ru F, Guan Y, Weng HJ, 
Geng Y, Undem BJ, Kollarik M, Chen ZF, Anderson DJ, Dong X. 2009. Sensory 
neuron-specific GPCR Mrgprs are itch receptor mediating chloroquine-induced 
pruritus. Cell 139(7): 1353-1365. 
104 
 
McIntosh JM, Hasson A, Spira ME, Gray WR, Li W, Marsh M, Hillyard DR, 
Olivera BM. 1995. A new family of conotoxins that block voltage-gated sodium 
channels. J Biol Chem. 270(28): 16796-16802. 
 
Miljanich GP. 2004. Ziconotide: neuronal calcium channel blocker for treating 
severe chronic pain. Curr Med Chem. 11(23): 3029-3040. 
 
Olivera BM, Cruz LJ. 2001. Conotoxins, in retrospect. Toxicon 39(1): 7-14. 
 
Olivera BM, Cruz LJ, de Santos V, Le Chiminant GW, Griffin D, Zeikus R, 
McIntosh JM, Galyean R, Varga J, Gray WR, Rivier J. 1987. Neuronal calcium 
channel antagonist. Discrimination between calcium channel subtypes using -
conotoxin from Conus magus venom. Biochemistry 26(8): 2086-2090. 
 
Puillandre N, Bouchet P, Duda TF Jr, Kauferstein S, Kohn AJ, Olivera BM, 
Watkins M, Meyer C. 2014. Molecular phylogeny and evolution of the cone snails 
(Gastropoda, Conoidea). Mol Phylogenet Evol. 78: 290-303. 
 
Shim WS, Tak MH, Lee MH, Kim M, Kim M, Koo JY, Lee CH, Kim M, Oh U. 
2007. TrpV1 mediates histamine-induced itching via the activation of 
phospholipase A2 and 12-lipoxygenase. J Neurosci. 27(9): 2331-2337. 
  
Shon KJ, Grilley MM, Marsh M, Yoshikami D, Hall AR, Kurz B, Gray WR, 
Imperial JS, Hillyard DR, Olivera BM. 1995. Purification, characterization and 
cloning of the lockjaw peptide from Conus purpurascens venom. Biochemistry 
34(15): 4913-4918. 
 
Shon KJ, Stocker M, Terlau H, Stühmer W, Jacobsen R, Walker C, Grilley M, 
Watkins M, Hillyard DR, Gray WR, Olivera BM. 1998. -Conotoxin PVIIA:  a 
peptide inhibiting the Shaker K+ channel. J Biol Chem. 273(1): 33-38. 
 
Teichert RW, Raghuraman S, Memon T, Cox JL, Foulkes T, Rivier JE, Olivera 
BM. 2012. Characterization of two neuronal subclasses through constellation 
pharmacology. Proc Natl Acad Sci. 109(31): 12758-12763. 
 
Wilson SR, Gerhold KA, Bifolck-Fisher A, Liu Q, Patel KN, Dong X, Bautista DM. 
2011. TRPA1 is required for histamine-independent, Mas-related G protein-
coupled receptor-mediated itch. Nat Neurosci. 14(5): 595-602. 
 
Zhou J. 2004. Norepinephrine transporter inhibitors and their therapeutic 
potential. Drugs Future 29(12): 1235-1244. 
